Literature DB >> 2673658

Cancer of the breast and reproductive tract in relation to use of oral contraceptives.

J J Schlesselman1.   

Abstract

Effects of oral contraception on cancers of the female breast and reproductive tract are critically reviewed from human studies reported since 1980. The cumulative risk of breast cancer through 59 years of age appears to bear no relationship to oral contraceptive (OC) use whatsoever. Studies restricted to women under age 45, however, raise concern about a possible adverse effect from OC use before a first-term pregnancy. A duration-related protective effect against endometrial cancer occurs from use of combined OCs. The risk is reduced by about 40% with 2 years of use, and by about 60% with 4 or more years of oral contraception. Oral contraception in excess of 3 years protects against ovarian cancer. Four years of use confers a 50% reduction in risk and 7 or more years of use confers a 60%-80% reduction in ovarian cancer risk. Studies of cervical dysplasia and carcinoma in situ suggest elevated risks with 2 or more years of OC use, although results are difficult to interpret in view of numerous factors that might distort the findings. The risk of invasive cervical cancer appear to be unaffected by up to 5 years of oral contraception. Beyond this, there is evidence suggesting an elevated risk which approaches a 2-fold increase at 10 years of use. Cancers of the vagina and fallopian tube are extremely rare. Their risks have yet to be characterized in relation to oral contraception.

Entities:  

Keywords:  Age Distribution; Age Factors; Biology; Body Weight; Breast Cancer; Cancer; Cervical Cancer; Cervical Effects; Cervix; Contraception; Contraception Continuation; Contraceptive Methods--beneficial effects; Contraceptive Methods--side effects; Contraceptive Usage; Demographic Factors; Diseases; Endocrine System; Endometrial Cancer; Estrogens--side effects; Family Planning; Fertility; Fertility Measurements; Genitalia; Genitalia, Female; Hormones; Incidence; Literature Review; Measurement; Neoplasms; Obesity; Oral Contraceptives--beneficial effects; Oral Contraceptives--side effects; Ovarian Cancer; Parity; Physiology; Population; Population Characteristics; Population Dynamics; Research Methodology; Risk Factors; Urogenital System; Uterus

Mesh:

Substances:

Year:  1989        PMID: 2673658     DOI: 10.1016/0010-7824(89)90025-5

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  10 in total

1.  Childbearing and use of oral contraceptives: impact of educational level. The Nordland Health Study.

Authors:  B K Jacobsen; E Lund; G Kvåle
Journal:  J Epidemiol Community Health       Date:  1992-06       Impact factor: 3.710

2.  Depot medroxyprogesterone and risk of breast cancer.

Authors:  R H Gray
Journal:  BMJ       Date:  1989-10-28

3.  Incidence trends for cancers of the breast, ovary, and corpus uteri in urban Shanghai, 1972-89.

Authors:  F Jin; X O Shu; S S Devesa; W Zheng; W J Blot; Y T Gao
Journal:  Cancer Causes Control       Date:  1993-07       Impact factor: 2.506

4.  Coffee and cancer: a prospective study of 43,000 Norwegian men and women.

Authors:  I Stensvold; B K Jacobsen
Journal:  Cancer Causes Control       Date:  1994-09       Impact factor: 2.506

Review 5.  Anogenital human papillomavirus infection. Changes in understanding and management.

Authors:  J W Sellors; C Law
Journal:  Can Fam Physician       Date:  1994-01       Impact factor: 3.275

6.  A sociobehavioural perspective on genetic testing and counselling for heritable breast, ovarian and colon cancer.

Authors:  K G Macdonald; B Doan; M Kelner; K M Taylor
Journal:  CMAJ       Date:  1996-02-15       Impact factor: 8.262

Review 7.  Infertility evaluation and management. Strategies for family physicians.

Authors:  Allison M Case
Journal:  Can Fam Physician       Date:  2003-11       Impact factor: 3.275

8.  Cyclical mastalgia as a marker of breast cancer susceptibility: results of a case-control study among French women.

Authors:  G Plu-Bureau; J C Thalabard; R Sitruk-Ware; B Asselain; P Mauvais-Jarvis
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

9.  Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism.

Authors:  W H Catherino; M H Jeng; V C Jordan
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

10.  Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk.

Authors:  Linda S Cook; Claire R Pestak; Andy Cy Leung; Helen Steed; Jill Nation; Kenneth Swenerton; Richard Gallagher; Anthony Magliocco; Martin Köbel; Angela Brooks-Wilson; Nhu Le
Journal:  Br J Cancer       Date:  2016-12-13       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.